CV Safety Gets Diabetes Drugs Approved, Not Sold, AstraZeneca Exec Notes
Executive Summary
Firms shouldn't lose sight of the need to build the commercial aspects of their type 2 diabetes drugs as they focus on reorienting clinical trials to include cardiovascular risk assessment, according to an AstraZeneca exec
You may also be interested in...
Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says
Sponsors must move beyond glycemic control if they want any new therapy for type 2 diabetes to be commercially viable, according to a Roche executive.
Glycemic Control Not Enough For New Diabetes Drugs, Roche Exec Says
Sponsors must move beyond glycemic control if they want any new therapy for type 2 diabetes to be commercially viable, according to a Roche executive.
AstraZeneca/Bristol's Diabetes Drug Onglyza Cleared
AstraZeneca hints that drug could be priced lower than Merck's blockbuster Januvia.